Papatheodoridi M. Rates and predictors of HBsAg loss after discontinuation of effective long-term Entecavir or Tenofovir therapy in non-cirrhotic HBeAg-negative Chronic Hepatitis B patients: Results from the DARING-B prospective Greek study. PS-159.
Immunogeniciteit en veiligheid van een tri- versus mono-antigeen hepatitis B-vaccin
jan 2022 | Hepatitis, Vaccinatie, Virale infecties